PGEN vs. CRSP, PTCT, ACAD, MENS, PCVX, KRYS, ARWR, ACLX, ADMA, and MIRM
Should you be buying Precigen stock or one of its competitors? The main competitors of Precigen include CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), Jyong Biotech (MENS), Vaxcyte (PCVX), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), ADMA Biologics (ADMA), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.
Precigen vs. Its Competitors
CRISPR Therapeutics (NASDAQ:CRSP) and Precigen (NASDAQ:PGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
CRISPR Therapeutics has a net margin of -1,229.43% compared to Precigen's net margin of -2,868.66%. CRISPR Therapeutics' return on equity of -20.05% beat Precigen's return on equity.
69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 47.1% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
CRISPR Therapeutics presently has a consensus target price of $71.60, indicating a potential upside of 38.48%. Precigen has a consensus target price of $8.25, indicating a potential upside of 109.66%. Given Precigen's stronger consensus rating and higher possible upside, analysts clearly believe Precigen is more favorable than CRISPR Therapeutics.
CRISPR Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500.
Precigen has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
In the previous week, CRISPR Therapeutics had 2 more articles in the media than Precigen. MarketBeat recorded 10 mentions for CRISPR Therapeutics and 8 mentions for Precigen. Precigen's average media sentiment score of 1.23 beat CRISPR Therapeutics' score of 0.84 indicating that Precigen is being referred to more favorably in the news media.
Summary
Precigen beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Precigen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precigen Competitors List
Related Companies and Tools
This page (NASDAQ:PGEN) was last updated on 9/10/2025 by MarketBeat.com Staff
Free PGEN Stock Alerts